BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8874202)

  • 21. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects.
    Sykes M; Harty MW; Szot GL; Pearson DA
    Blood; 1994 May; 83(9):2560-9. PubMed ID: 7909457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lethal murine graft-versus-host disease induced by donor gamma/delta expressing T cells with specificity for host nonclassical major histocompatibility complex class Ib antigens.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Barrett TA; Bluestone JA; Vallera DA
    Blood; 1996 Jan; 87(2):827-37. PubMed ID: 8555509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of lethal acute graft-versus-host disease in mice by oral administration of T helper 1 inhibitor, TAK-603.
    Lu Y; Sakamaki S; Kuroda H; Kusakabe T; Konuma Y; Akiyama T; Fujimi A; Takemoto N; Nishiie K; Matsunaga T; Hirayama Y; Kato J; Kon S; Kogawa K; Niitsu Y
    Blood; 2001 Feb; 97(4):1123-30. PubMed ID: 11159546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J-->C57BL/6J x bm12)F1 mice.
    Brown GR; Lee E; Thiele DL
    J Immunol; 2002 Mar; 168(6):3065-71. PubMed ID: 11884480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
    Jones SC; Friedman TM; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease.
    Schultz KR; Bader S; Paquet J; Li W
    Blood; 1995 Dec; 86(11):4344-52. PubMed ID: 7492796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-γ pathway.
    Park HB; Oh K; Garmaa N; Seo MW; Byoun OJ; Lee HY; Lee DS
    Transplantation; 2010 Oct; 90(8):825-35. PubMed ID: 20697326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease.
    Aharoni R; Schlegel PG; Teitelbaum D; Roikhel-Karpov O; Chen Y; Arnon R; Sela M; Chao NJ
    Immunol Lett; 1997 Jul; 58(2):79-87. PubMed ID: 9271317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
    Berger M; Wettstein PJ; Korngold R
    Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection from T helper cell-mediated graft-versus-host disease by the presence of an MHC class I alloantigen is associated with perturbation of MHC class II-restricted responses by class I-derived peptides.
    Leibnitz RR; Lipsky PE; Thiele DL
    J Immunol; 1995 Aug; 155(4):1784-95. PubMed ID: 7636234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
    Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin-12 prevents severe acute graft-versus-host disease (GVHD) and GVHD-associated immune dysfunction in a fully major histocompatibility complex haplotype-mismatched murine bone marrow transplantation model.
    Yang YG; Dey B; Sergio JJ; Sykes M
    Transplantation; 1997 Nov; 64(9):1343-52. PubMed ID: 9371678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of the Immunoproteasome Subunit LMP7 with ONX 0914 Ameliorates Graft-versus-Host Disease in an MHC-Matched Minor Histocompatibility Antigen-Disparate Murine Model.
    Zilberberg J; Matos J; Dziopa E; Dziopa L; Yang Z; Kirk CJ; Assefnia S; Korngold R
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1555-64. PubMed ID: 26093043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease.
    Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
    J Immunol; 2005 Mar; 174(5):3051-8. PubMed ID: 15728519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
    Blazar BR; Taylor PA; Snover DC; Bluestone JA; Vallera DA
    J Immunol; 1993 Jan; 150(1):265-77. PubMed ID: 8417127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Major histocompatibility complex-mismatched allogeneic bone marrow transplantation using perforin and/or Fas ligand double-defective CD4(+) donor T cells: involvement of cytotoxic function by donor lymphocytes prior to graft-versus-host disease pathogenesis.
    Jiang Z; Podack E; Levy RB
    Blood; 2001 Jul; 98(2):390-7. PubMed ID: 11435308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.
    Sykes M; Abraham VS; Harty MW; Pearson DA
    J Immunol; 1993 Jan; 150(1):197-205. PubMed ID: 8093257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.